Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

FT538

Cell therapy (NK cells) · Kills target cells · developed by Fate Therapeutics

Phase 1 Most advanced trial (none active)
FATE Developer
1 Registered trials

What is FT538?

FT538 is an allogeneic natural killer (NK) cell therapy derived from a clonal induced pluripotent stem cell line and engineered to express a high-affinity non-cleavable CD16 Fc receptor and an IL-15/IL-15 receptor alpha fusion, with CD38 expression eliminated. It binds stress-induced ligands on tumor cells and, with monoclonal antibodies, mediates antibody-dependent cellular cytotoxicity. It is studied in adult patients with solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy (NK cells)
Mechanism
Kills target cells
Pathways
antibody-dependent cellular cytotoxicity (ADCC), NK cell cytokine and chemokine secretion, T-cell activation and recruitment
Therapy area
Oncology
Developer
Fate Therapeutics (FATE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05069935 Phase 1 Solid Tumor, Adult Terminated FATE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Solid Tumor, Adult

More from Fate Therapeutics

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the FATE page.

Follow FATE, the company behind FT538

See FATE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

FATE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.